Status:
COMPLETED
Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD
Lead Sponsor:
Università degli Studi di Ferrara
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
Exacerbations are important events in the natural history of chronic obstructive pulmonary disease (COPD). Beside the acute (and prolonged) clinical impact, there is evidence that exacerbations negati...
Eligibility Criteria
Inclusion
- Sixty stable moderate COPD patients (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2) requiring regular treatment with long-acting bronchodilators, according to international guidelines.
- GOLD stage 2 COPD patients will be enrolled providing they were steroid-free for the last 4 months
Exclusion
- Atopy
- Asthma
- Concomitant lung diseases (e.g. lung cancer)
- Acute infections of the respiratory tree in the previous 3 months including COPD exacerbation.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01213693
Start Date
May 1 2009
End Date
November 1 2013
Last Update
April 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Centre on Asthma and COPD - Department of Clinical and Experimental Medicine - Section of Respiratory Disease - University of Ferrara
Ferrara, Italy, 44121